The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
Open accessAbstract
BACKGROUND: Antiretroviral drugs reduce viral replication and can reduce mother-to-child transmission of HIV either by lowering plasma viral load in pregnant women or through post-exposure prophylaxis in their newborns. In rich countries, highly active antiretroviral therapy (HAART) which usually comprises three drugs, has reduced the mother-to-child transmission rates to around 1-2%, but HAART is not always available in low- and middle-income countries. In these countries, various simpler and less costly antiretroviral regimens have been offered to pregnant women or to their newborn babies, or to both. OBJECTIVES: To determine whether, and to what extent, antiretroviral regimens aimed at decreasing the risk of mother-to-child transmission of HIV infection achieve a clinically useful decrease in transmission risk, and what effect these interventions have on maternal and infant mortality and morbidity. SEARCH STRATEGY: We sought to identify all relevant studies regardless of language or publication status by searching the Cochrane HIV/AIDS Review Group Trials Register, The Cochrane Library, MEDLINE, EMBASE and AIDSearch and relevant conference abstracts. We also contacted research organizations and experts in the field for unpublished and ongoing studies. The original review search strategy was conducted in 2002 and updated in 2006 and again in 2009. SELECTION CRITERIA: Randomised controlled trials of any antiretroviral regimen aimed at decreasing the risk of mother-to-child transmission of HIV infection compared with placebo or no treatment, or compared with another antiretroviral regimen. DATA COLLECTION AND ANALYSIS: Two authors independently selected relevant studies, extracted data and assessed trial quality. For the primary outcomes, we used survival analysis to estimate the probability of infants being infected with HIV (the observed proportion) at various specific time-points and calculated efficacy at a specific time as the relative reduction in the proportion infected. Efficacy, at a specific time, is defined as the preventive fraction in the exposed group compared to the reference group, which is the relative reduction in the proportion infected: 1-(Re/Rf). For those studies where efficacy and hence confidence intervals were not calculated, we calculated the approximate confidence intervals for the efficacy using recommended methods. For analysis of results that are not based on survival analyses we present the relative risk for each trial outcome based on the number randomised. No meta-analysis was conducted as no trial assessed identical drug regimens. MAIN RESULTS: Twenty-five trials including 18,901 participants with a median trial sample size of 627 ranging from 50 to 1,844 participants were included in this update. Twenty-two trials randomised mothers (18 pre-natally and four in labour) and followed up their infants, and three trials randomised infants. The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial. We present the results stratified by regimen and type of feeding.Antiretrovirals versus placebo In breastfeeding populations, three trials found that:ZDV given to mothers from 36 to 38 weeks gestation, during labour and for 7 days after delivery significantly reduced HIV infection at 4-8 weeks (Efficacy 32.00%; 95% CI 1.50 to 62.50), 3 to 4 months (Efficacy 33.07%; 95% CI 5.57 to 60.57), 6 months (Efficacy 34.55%; 95% CI 9.05 to 60.05), 12 months (Efficacy 34.31%; 95% CI 9.30 to 59.32) and 18 months (Efficacy 29.74%; 95% CI 2.73 to 56.75).ZDV given to mothers from 36 weeks gestation and during labour significantly reduced HIV infection at 4 to 8 weeks (Efficacy 43.78%; 95% CI 8.78 to 78.78) and 3 to 4 months (Efficacy 36.95%; 95% CI 2.94 to 70.96) but not at birth.ZDV plus lamivudine (3TC) given to mothers from 36 weeks gestation, during labour and for 7 days after delivery and to babies for the first 7 days after birth (PETRA 'regimen A') significantly reduced HIV infection (Efficacy 62.75%; 95% CI 40.76 to 84.74) and a combined endpoint of HIV infection or death (Efficacy 62.75 [, ]61.00%; 95% CI 40.76 to 84.74) at 4 to 8 weeks but these effects were not sustained at 18 months.ZDV plus 3TC given to mothers from the start of labour until 7 days after delivery and to babies for the first 7 days after birth (PETRA 'regimen B') significantly reduced HIV infection (Efficacy 41.83%; 95% CI 12.82 to 70.84) and HIV infection or death at 4 to 8 weeks (Efficacy 35.91%; 95% CI 8.41 to 63.41) but the effects were not sustained at 18 months.ZDV plus 3TC given to mothers during labour only (PETRA 'regimen C') with no treatment to babies did not reduce the risk of HIV infection at either 4 to 8 weeks or 18 months.In non-breastfeeding populations, three trials found that:ZDV given to mothers from 14 to 34 weeks gestation and during labour and to babies for the firs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Levels and Trends in Child Mortality : Report 2018
Hug, L., Dharrow, D., Zhong, K., & You, D. (2017) · Cited by 848
Sperling, R. S., Shapiro, D. E., Coombs, R. W., Todd, J. A., Herman, S. A., McSherry, G. D., O'Sullivan, M. J., Van Dyke, R. B., Jimenez, E., Rouzioux, C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352201 · Cited by 803
Levels and trends in child mortality, 1990–2009
You, D., Jones, G., Hill, K., Wardlaw, T., & Chopra, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61429-8 · Cited by 790
Risk of human immunodeficiency virus type 1 transmission through breastfeeding
Dunn, D. T., Newell, M. L., Ades, A. E., & Peckham, C. S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92115-v · Cited by 790
Shaffer, N., Chuachoowong, R., Mock, P. A., Bhadrakom, C., Siriwasin, W., Young, N. L., Chotpitayasunondh, T., Chearskul, S., Roongpisuthipong, A., Chinayon, P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10411-7 · Cited by 785
(1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401301 · Cited by 742
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., Firtion, G., Ciraru-Vigneron, N., Lacroix, C., Rouzioux, C., Mandelbrot, L., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07219-0 · Cited by 661
Wiktor, S. Z., Ekpini, E., Karon, J. M., Nkengasong, J., Maurice, C., Severin, S. T., Roels, T. H., Kouassi, M. K., Lackritz, E. M., Coulibaly, I.-M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10412-9 · Cited by 541
Wade, N. A., Birkhead, G. S., Warren, B. L., Charbonneau, T. T., French, P. T., Wang, L., Baum, J. B., Tesoriero, J. M., & Savicki, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392001 · Cited by 535
Jackson, J. B., Musoke, P., Fleming, T., Guay, L. A., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Owor, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14341-3 · Cited by 524
Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana
Shapiro, R. L., Hughes, M. D., Ogwu, A., Kitch, D., Lockman, S., Moffat, C., Makhema, J., Moyo, S., Thior, I., McIntosh, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907736 · Cited by 521
Lallemant, M., Jourdain, G., Le Coeur, S., Mary, J. Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K., & Thaineua, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033500 · Cited by 460
(2002) · The Lancet · doi:10.1016/s0140-6736(02)08214-4 · Cited by 459
AIDS across Europe, 1994–98: the EuroSIDA study
Mocroft, A., Katlama, C., Johnson, A., Pradier, C., Antunes, F., Mulcahy, F., Chiesi, A., Phillips, A., Kirk, O., & Lundgren, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02504-6 · Cited by 453
Diethylstilbestrol Revisited: A Review of the Long-Term Health Effects
Giusti, R. M., Iwamoto, K., & Hatch, E. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-10-199505150-00008 · Cited by 450
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Obstetrical Factors and the Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child
Landesman, S. H., Kalish, L. A., Burns, D. N., Minkoff, H., Fox, H. E., Zorrilla, C., Garcia, P., Fowler, M. G., Mofenson, L., & Tuomala, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342501 · Cited by 435
Lallemant, M., Jourdain, G., Le Coeur, S., Kim, S., Koetsawang, S., Comeau, A. M., Phoolcharoen, W., Essex, M., McIntosh, K., & Vithayasai, V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431401 · Cited by 425
Risk factors for mother-to-child transmission of HIV-1
Study, E. C. (1992) · The Lancet · doi:10.1016/0140-6736(92)90534-a · Cited by 418
Maternal vitamin A deficiency and mother-to-child transmission of HIV-1
Semba, R. D., Chiphangwi, J. D., Miotti, P. G., Dallabetta, G. A., Hoover, D. R., Canner, J. K., & Saah, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)93056-2 · Cited by 417
Thior, I., Lockman, S., Smeaton, L. M., Shapiro, R. L., Wester, C., Heymann, S. J., Gilbert, P. B., Stevens, L., Peter, T., Kim, S., et al. (2006) · JAMA · doi:10.1001/jama.296.7.794 · Cited by 413
(2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70288-7 · Cited by 405
Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1
Mandelbrot, L. (2001) · JAMA · doi:10.1001/jama.285.16.2083 · Cited by 392
Kenyon, S., Pike, K., Jones, D., Brocklehurst, P., Marlow, N., Salt, A., & Taylor, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61203-9 · Cited by 383
Self-citationDorenbaum, A. (2002) · JAMA · doi:10.1001/jama.288.2.189 · Cited by 373
HIV Transmission Through Breastfeeding: A Study in Malawi
Miotti, P. G., Taha, T. E. T., Kumwenda, N. I., Broadhead, R., Mtimavalye, L. A. R., Van der Hoeven, L., Chiphangwi, J. D., Liomba, G., & Biggar, R. J. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200003000-00011 · Cited by 364
Moodley, D., Moodley, J., Coovadia, H., Gray, G., McIntyre, J., Hofmyer, J., Nikodem, C., Hall, D., Gigliotti, M., Robinson, P., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/367898 · Cited by 347
&NA; (1995) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199504120-00011 · Cited by 291
Marseille, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07420-6 · Cited by 266
Taha, T. E., Kumwenda, N. I., Gibbons, A., Broadhead, R. L., Fiscus, S., Lema, V., Liomba, G., Nkhoma, C., Miotti, P. G., & Hoover, D. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14538-2 · Cited by 205
Leroy, V., Karon, J. M., Alioum, A., Ekpini, E. R., Meda, N., Greenberg, A. E., Msellati, P., Hudgens, M., Dabis, F., & Wiktor, S. Z. (2002) · AIDS · doi:10.1097/00002030-200203080-00016 · Cited by 167
MINKOFF, H. L., Burns, D., Landesman, S. H., Youchah, J., Goedert, J. J., Nugent, R. P., Muenz, L. R., & Willoughby, A. D. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90286-4 · Cited by 148
Meeting international goals in child survival and HIV/AIDS
Walker, N., Schwartländer, B., & Bryce, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09550-8 · Cited by 132
Bartlett, J. A., & Shao, J. F. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70227-0 · Cited by 115
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya
Kiarie, J. N., Kreiss, J. K., Richardson, B. A., & John-Stewart, G. C. (2003) · AIDS · doi:10.1097/00002030-200301030-00009 · Cited by 111
Gray, G., Urban, M. F., Chersich, M., et al. (2005) · AIDS · doi:10.1097/01.aids.0000180100.42770.a7 · Cited by 108
Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution
Siegfried, N., Clarke, M. J., & Volmink, J. A. (2005) · BMJ · doi:10.1136/bmj.331.7519.742 · Cited by 74
Self-citationProtecting the Next Generation — Eliminating Perinatal HIV-1 Infection
MOFENSON, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejme1004406 · Cited by 72
Lehman, D. A., Chung, M. H., John-Stewart, G. C., Richardson, B. A., Kiarie, J. N., Kinuthia, J., & Overbaugh, J. (2008) · AIDS · doi:10.1097/qad.0b013e328302cc11 · Cited by 67
Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001146.pub3 · Cited by 66
Alioum, A., Dabis, F., Dequae-Merchadou, L., Haverkamp, G., Hudgens, M. G., Hughes, J. P., Karon, J. M., Leroy, V., Newell, M., Richardson, B. A., et al. (2001) · Statistics in Medicine · doi:10.1002/sim.1076 · Cited by 57
Jamieson, D. J., Sibailly, T. S., Sadek, R., Roels, T. H., Ekpini, E., Boni-Ouattara, E., Karon, J. M., Nkengasong, J. N., Greenberg, A. E., & Wiktor, S. Z. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00011 · Cited by 49
Bhadrakom, C., Simonds, R. J., Mei, J. V., Asavapiriyanont, S., Sangtawesin, V., Vanprapar, N., Moore, K. H. P., Young, N. L., Hannon, W. H., Mastro, T. D., et al. (2000) · AIDS · doi:10.1097/00002030-200003310-00006 · Cited by 28
Chi, B. H., Chintu, N., Cantrell, R. A., Kankasa, C., Kruse, G. R., Mbewe, F., Sinkala, M., Smith, P. J., Stringer, E. M., & Stringer, J. S. A. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181743969 · Cited by 21
Thistle, P., Spitzer, R. F., Glazier, R. H., Pilon, R., Arbess, G., Simor, A. E., Boyle, E., Chitsike, I., Chipato, T., Gottesman, M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508869 · Cited by 21
Cited by
Bhutta, Z. A., Das, J. K., Bahl, R., Lawn, J. E., Salam, R. A., Paul, V. K., Sankar, M. J., Blencowe, H., Rizvi, A., Chou, V. B., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60792-3 · Cited by 1,367
Renfrew, M. J., McFadden, A., Bastos, M. H., Campbell, J., Channon, A. A., Cheung, N. F., Silva, D. R. A. D., Downe, S., Kennedy, H. P., Malata, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60789-3 · Cited by 1,297
Estimating per-act HIV transmission risk: a systematic review
Patel, P., Borkowf, C. B., Brooks, J. T., Lasry, A., Lansky, A., & Mermin, J. (2014) · AIDS · doi:10.1097/qad.0000000000000298 · Cited by 748
Barriers for conducting clinical trials in developing countries—A systematic review
Alemayehu, C., Mitchell, G., & Nikles, J. (2018) · International Journal for Equity in Health · doi:10.1186/s12939-018-0748-6 · Cited by 406
The Spectrum of Fungi That Infects Humans
Kohler, J. R., Casadevall, A., & Perfect, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019273 · Cited by 364
Metadata
- Authors
- Siegfried, N., van der Merwe, L., Brocklehurst, P., & Sint, T. T.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-07-06
- Volume
- 2011
- Issue
- 7
- Pages
- CD003510-CD003510
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2102628929
- Cited by
- 325
- References
- 48
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.